Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden Tackles Regulatory Barriers To Decentralized Trials

MPA Offers Free Advice On The Dos And Don’ts Of Virtual Trials

Executive Summary

The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials. 

You may also be interested in...



Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?

Companies like Bayer and AstraZeneca are seeing what a difference decentralization makes as CVS is rapidly expanding its clinical research business.

Denmark Outlines Vision For Decentralized Trials Beyond COVID-19

The Danish medicines regulator has set out its expectations on key elements of decentralized clinical trials as part of Denmark’s ongoing effort to develop a robust regulatory framework in this area.

Denmark Tackles ‘All Talk And No Action’ On Decentralized Clinical Trials

Danish regulators tell the Pink Sheet they want to know what is holding companies back from submitting applications for decentralized clinical trials and are keen to find creative solutions to possible hurdles.

Related Content

Topics

UsernamePublicRestriction

Register

PS145139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel